peginterferon alfa-2a and ribavirin

DRUG4 trials

Sponsors

National Taiwan University Hospital, Carelon Research, University of Ulm, Pusan National University Yangsan Hospital

Conditions

Chronic Hepatitis CHepatitis CHepatitis C, ChronicLiver DiseasesThalassemiaVirus Diseases

Phase 2

Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)

CompletedNCT00502788

Carelon ResearchHepatitis C, Thalassemia

Start: 2003-05-31End: 2006-08-31Updated: 2014-03-04

Phase 4

Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C

CompletedNCT00491244

National Taiwan University HospitalChronic Hepatitis C

Start: 2007-06-30End: 2013-09-30Updated: 2014-02-10

Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C

CompletedNCT00948220

University of UlmHepatitis C, Chronic, Liver Diseases, Virus Diseases

Start: 2003-07-31End: 2008-03-31Updated: 2011-06-07

PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)

Pusan National University Yangsan HospitalChronic Hepatitis C

Start: 2010-01-31End: 2012-12-31Target: 164Updated: 2012-04-20

Related Papers

Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial

Gut2014-04-1942 citations

Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.

2013-12-0173 citations